![]() |
ChairBrenda de Winter |
![]() Contact Us |
![]() |
Vice-ChairJean-Baptiste Woillard |
Pharmacometrics (PM) has become progressively a key science in the drug development process and increasingly gaining importance in clinical study design and patient care, e.g. to inform dosing decisions within the framework of thereapeutic drug monitoring. It involves the development of (PB)PK or PK/PD or PK/PD/PG models that provide knowledge about the behaviour of a drug and how it can be optimally used. We believe pharmacometrics can help to describe or predict drug concentrations, their relationship with drug effects and clinical impacts. The application of PM models, e.g. using software tools, can also be very helpful to render personalized dose adjustments based on a patient’s individual parameters available in the clinical setting.
The aims of the pharmacometrics committee are:
The committee is planning to organize an interactive workshop for the meeting of 2021 in Rome to increase the use of PMx in the IATDMCT society. This meeting is targeted on people not involved in PK/PD modelling at this moment.
To achieve more efficient use of PK/PD data we will collaborate with other committees, and organize joint symposia for upcoming conferences.
Educational tools we are working on:
The committee is completely renewed at the congress in Iguazu and the period afterwards. The new members updated the text on the website and organized interesting meetings for the upcoming congress.
We published the following articles in the IATDMCT COMPASS: